Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Troikaa Pharmaceuticals (Troikaa) is expecting to receive US patent for drug delivery form of Diclofenac injections-Dyanapar AQ, reported PTI news.
Subscribe to our email newsletter
Diclofenac injections are used for management of painful inflammatory conditions. Dynapar AQ is a high concentration, low viscosity injection of diclofenac sodium delivering the full therapeutic dose of diclofenac in just one millilitre injection volume. Diclofenac injection available in PFS (pre-filled syringe) form.
Ketan Patel, managing director of Troikaa, said: “Troikaa is shortly to get US patent for its Dyanapar AQ 1ml injections, as proceedings at the FDA have got over, we are just awaiting certificate and confirmation from them (FDA). Proceeding for patent in Israel for this injection is also almost over and it would be received soon,” reports the agency.
“Last month we had got the Eurasian patent for this injection, that will enable us to cover almost all CIS countries including Russia,” MD added.